These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 32638205)
1. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205 [TBL] [Abstract][Full Text] [Related]
2. Antimuscarinic use and discontinuation in an older adult population. Vouri SM; Schootman M; Strope SA; Xian H; Olsen MA Arch Gerontol Geriatr; 2019; 80():1-11. PubMed ID: 30268971 [TBL] [Abstract][Full Text] [Related]
3. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830 [TBL] [Abstract][Full Text] [Related]
4. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724 [TBL] [Abstract][Full Text] [Related]
5. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. Wagg A; Compion G; Fahey A; Siddiqui E BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769 [TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051 [TBL] [Abstract][Full Text] [Related]
7. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072 [TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538 [TBL] [Abstract][Full Text] [Related]
10. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. Sura S; Shiozawa A; Ng D; Aparasu RR J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158 [TBL] [Abstract][Full Text] [Related]
11. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826 [TBL] [Abstract][Full Text] [Related]
12. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR J Gen Intern Med; 2020 Jul; 35(7):2084-2093. PubMed ID: 32026255 [TBL] [Abstract][Full Text] [Related]
13. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members. Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920 [TBL] [Abstract][Full Text] [Related]
14. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis]. Krunal Vishavadia KV; Sandip Solanki SS; Hiren Prajapati HP; Madhu Sharma MS Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707 [TBL] [Abstract][Full Text] [Related]
15. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial. Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387 [TBL] [Abstract][Full Text] [Related]
16. A Nordic registry-based study of drug treatment patterns in overactive bladder patients. Milsom I; Schiotz HA; Svensson M; Kilany S; Hansson F Scand J Urol; 2019 Aug; 53(4):246-254. PubMed ID: 31195868 [No Abstract] [Full Text] [Related]
17. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly. Rangganata E; Widia F; Rahardjo HE Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336 [TBL] [Abstract][Full Text] [Related]
18. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Zinner N; Kobashi KC; Ebinger U; Viegas A; Egermark M; Quebe-Fehling E; Koochaki P Int J Clin Pract; 2008 Nov; 62(11):1664-74. PubMed ID: 18811599 [TBL] [Abstract][Full Text] [Related]
19. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653 [TBL] [Abstract][Full Text] [Related]
20. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Kachru N; Sura S; Chatterjee S; Aparasu RR Drugs Aging; 2016 Oct; 33(10):755-763. PubMed ID: 27681701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]